Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSF
Dates
study started
completion around
Principal Investigator
by Dawn S. Eliashiv, MD (ucla)
Headshot of Dawn S. Eliashiv
Dawn S. Eliashiv

Description

Summary

The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.

Keywords

Epilepsy, Deep Brain Stimulation, DBS, EPAS, Activa™ PC and Percept™ PC Neurostimulation Systems

Eligibility

Locations

  • University of California Los Angeles (UCLA) accepting new patients
    Los Angeles California 90095-1406 United States
  • University of California San Francisco UCSF Medical Center accepting new patients
    San Francisco California 94143 United States
  • Stanford Hospital & Clinics accepting new patients
    Stanford California 94305 United States

Lead Scientist at University of California Health

  • Dawn S. Eliashiv, MD (ucla)
    Professor of Clinical, Neurology, Medicine. Authored (or co-authored) 41 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
MedtronicNeuro
ID
NCT03900468
Study Type
Interventional
Participants
Expecting 140 study participants
Last Updated